Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer. It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma. In addition, the company develops CX-4945-AV06, a phase II, double blind randomized, controlled study to evaluate the safety and efficacy of CX-4945 in hospitalized adults with COVID-19. Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.
तुलना करने के लिए मीट्रिक्स | 6492 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध6492पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −10.7x | 0.0x | −0.4x | |
PEG अनुपात | 5.35 | 0.00 | 0.00 | |
क़ीमत/बुक | 3.2x | 0.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 3,134.9x | 0.0x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 0.0% | 54.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 0.0% | 9.3% | अनलॉक करें |